ESC Heart Failure (Feb 2024)

European Society of Cardiology guidelines and 1 year outcomes of acute heart failure treatment in Central Asia and Europe

  • Tamila Abdurashidova,
  • Martin Müller,
  • Sara Schukraft,
  • Nisha Soborun,
  • Barbara Pitta‐Gros,
  • John Kikoïne,
  • Henri Lu,
  • Zalina Chazymova,
  • Kanzaada Dzhorupbekova,
  • Medet Beishenkulov,
  • Georgios Tzimas,
  • Matthias Kirsch,
  • Peter Vollenweider,
  • Marie Mean,
  • Pierre Monney,
  • Roger Hullin

DOI
https://doi.org/10.1002/ehf2.14591
Journal volume & issue
Vol. 11, no. 1
pp. 483 – 491

Abstract

Read online

Abstract Aims Outcomes reported for patients with hospitalization for acute heart failure (AHF) treatment vary worldwide. Ethnicity‐associated characteristics may explain this observation. This observational study compares characteristics and 1‐year outcomes of Kyrgyz and Swiss AHF patients against the background of European Society of Cardiology guidelines‐based cardiovascular care established in both countries. Methods and results The primary endpoint was 1 year all‐cause mortality (ACM); the secondary endpoint was 1 year ACM or HF‐related rehospitalization. A total of 538 Kyrgyz and 537 Swiss AHF patients were included. Kyrgyz patients were younger (64.0 vs. 83.0 years, P mild aortic stenosis was more prevalent (P < 0.001). Other valvular pathologies were more prevalent in Kyrgyz patients (P < 0.001). At discharge, more Swiss patients were on vasodilatory treatment (P < 0.006), while mineralocorticoid receptor antagonists (P = 0.001), beta‐blockers (P = 0.001), or loop diuretics (P < 0.001) were less often prescribed. In Kyrgyz patients, unadjusted odds for the primary and secondary endpoints were lower [odds ratio (OR) 0.68, 95% confidence interval (CI): 0.51–0.90, P = 0.008; OR 0.72, 95% CI: 0.56–0.91, P = 0.006, respectively]. After adjustment for age and LVEF, no difference remained (primary endpoint: OR 1.03, 95% CI: 0.71–1.49, P = 0.894; secondary endpoint: OR 0.82, 95% CI: 0.60–1.12, P = 0.206). Conclusions On the background of identical guidelines, age‐ and LVEF‐adjusted outcomes were not different between Central Asian and Western European AHF patients despite of large ethnical disparity.

Keywords